» Articles » PMID: 22728313

Toward Tailored Exosomes: the Exosomal Tetraspanin Web Contributes to Target Cell Selection

Overview
Publisher Elsevier
Date 2012 Jun 26
PMID 22728313
Citations 354
Authors
Affiliations
Soon will be listed here.
Abstract

Exosomes are discussed as potent therapeutics due to efficient transfer of proteins, mRNA and miRNA in selective targets. However, therapeutic exosome application requires knowledge on target structures to avoid undue delivery. Previous work suggesting exosomal tetraspanin-integrin complexes to be involved in target cell binding, we aimed to control this hypothesis and to define target cell ligands. Exosomes are rich in tetraspanins that associate besides other molecules with integrins. Co-immunoprecipitation of exosome lysates from rat tumor lines that differ only with respect to Tspan8 and beta4 revealed promiscuity of tetraspanin-integrin associations, but also few preferential interactions like that of Tspan8 with alpha4 and beta4 integrin chains. These minor differences in exosomal tetraspanin-complexes strongly influence target cell selection in vitro and in vivo, efficient exosome-uptake being seen in hematopoietic cells and solid organs. Exosomes expressing the Tspan8-alpha4 complex are most readily taken up by endothelial and pancreas cells, CD54 serving as a major ligand. Selectivity of uptake was confirmed with exosomes from an alpha4 cDNA transfected Tspan8(+) lymph node stroma line. Distinct from exosomes from the parental line, the latter preferentially targeted endothelial cells and in vivo the pancreas. Importantly, pulldown experiments provided strong evidence that exosome-uptake occurs in internalization-prone membrane domains. This is the first report on the exosomal tetraspanin web contributing to target cell selection such that predictions can be made on potential targets, which will facilitate tailoring exosomes for drug delivery.

Citing Articles

Mitochondria-targeted nanovesicles for ursodeoxycholic acid delivery to combat neurodegeneration by ameliorating mitochondrial dysfunction.

Zhang S, Li M, Li Y, Yang S, Wang J, Ren X J Nanobiotechnology. 2025; 23(1):202.

PMID: 40069803 PMC: 11895296. DOI: 10.1186/s12951-025-03258-5.


Current challenges surrounding exosome treatments.

Tzng E, Bayardo N, Yang P Extracell Vesicle. 2025; 2:100023.

PMID: 40027080 PMC: 11870656. DOI: 10.1016/j.vesic.2023.100023.


Extracellular vesicles in tumor immunity: mechanisms and novel insights.

Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.

PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.


Roles and Potential Mechanisms of Endothelial Cell-Derived Extracellular Vesicles in Ischemic Stroke.

Yu X, Huang Y, Li C Transl Stroke Res. 2025; .

PMID: 39918683 DOI: 10.1007/s12975-025-01334-4.


Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.

Meena S, Kosgei B, Soko G, Tingjun C, Chambuso R, Mwaiselage J NPJ Vaccines. 2025; 10(1):18.

PMID: 39870669 PMC: 11772600. DOI: 10.1038/s41541-024-01035-3.